<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321292</url>
  </required_header>
  <id_info>
    <org_study_id>Hayam Fathy Mohammad 2</org_study_id>
    <nct_id>NCT03321292</nct_id>
  </id_info>
  <brief_title>L-arginine in Treatment of Intrauterine Growth Restriction</brief_title>
  <official_title>Effect of L-Arginine on Intrauterine Growth Restriction Fetuses Measured by Birth Weight: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrauterine growth restriction is an important problem in neonatal care. Intrauterine growth
      restriction (IUGR) is defined as a fetal weight below the 10th percentile for gestational
      age. One of the main causes of IUGR is placental insufficiency.

      Nitric oxide(NO) increases placental blood flow. So,it might be useful to improve IUGR
      pregnancy outcome .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population includes pregnant women attending Antenatal care clinic of Ain Shams
      University Maternity Hospital who first time diagnosed of IUGR at our antenatal care
      outpatient clinic either referred for this cause After confirm diagnosis of IUGR and
      distributing patient into two groups Patient in first group will receive oral L-arginine
      3000mg/day till delivery and Acetylesalicylic acid 75mg once daily.

      Patients in second group will receive Acetylesalicylic acid 75mg once daily. then follow up
      of both group by:

        1. Daily fetal movement counting

        2. Day after day CTG

        3. Doppler twice weekly

        4. Pelvic u/s weekly for:

      A) Head circumference, Abdominal circumference, femur length B) Fetal weight C) Liquor
      amount: Amniotic Fluid Index Or MeanVertical Pocket

      Decision of delivery will be determined when:

      A) Fetal distress (non stress CTG) B) Mother starts labour C) Reversed umbilical artery
      Doppler.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group(A) 130 pregnant women diagnosed with IUGR will receive L-arginine and Acetylesalicylic acid 75mg Group(B) 130 pregnant women diagnosed with IUGR will receive Acetylesalicylic acid 75mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birth weight</measure>
    <time_frame>15 min</time_frame>
    <description>neonatal birth weight will be measured immediately following delivery and compared with the estimated fetal weight measured by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>at one and five minute after birth.</time_frame>
    <description>The Apgar scale is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are (Appearance, Pulse, Grimace, Activity, Respiration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amniotic fluid index</measure>
    <time_frame>evey one week from 28 weeks gestation till 40 weeks gestation</time_frame>
    <description>Amniotic fluid index (sum of the vertical diameter of the four pocket of amniotic fluid )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical artery Doppler</measure>
    <time_frame>every from 28 weeks gestation till 40 weeks gestation</time_frame>
    <description>umbilical artery Doppler will measured by two dimensional ultrasound power Doppler twice weekly for the presence of any abnormality as: marked decreased diastolic blood flow, absent or reversed diastolic blood flow.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Intrauterine Growth Restriction Asymmetrical</condition>
  <arm_group>
    <arm_group_label>L-arginine and Acetylesalicylic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylesalicylic acid75mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine 1000 mg and Acetylesalicylic acid75mg</intervention_name>
    <description>l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.</description>
    <arm_group_label>L-arginine and Acetylesalicylic acid</arm_group_label>
    <other_name>L- arginine 1000mg capsule and Ezacard 75 mg tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid 75 mg</intervention_name>
    <description>acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.</description>
    <arm_group_label>Acetylesalicylic acid75mg</arm_group_label>
    <other_name>Ezacard 75mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All pregnant women diagnosed with IUGR from 28 weeks

          -  Singleton pregnancy

          -  No maternal systemic disease

          -  No congenital fetal malformation

          -  Estimated fetal weight below 10th percentile

        Exclusion Criteria:

          -  All pregnant woman diagnosed with IUGR before 28 weeks

          -  Multiple pregnancy

          -  Maternal systemic disease

          -  Congenital fetal malformation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hayam FA Mohammad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hayam FA Mohammad, MD</last_name>
    <phone>002-01000069593</phone>
    <email>fatihy_9999@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manar LO Kamal, MBBCH</last_name>
    <phone>002-01274252819</phone>
    <email>Manaryunis88@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayam FA Mohammad, MD</last_name>
      <phone>002-01000069593</phone>
      <email>fatihy_9999@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Manar LO Kamal, MBBCH</last_name>
      <phone>002-01274252819</phone>
      <email>Manaryunis88@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hayam Fathy Mohammad</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology , Ain Shams University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

